UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 2, 2011 (April 30, 2011)
Alnylam Pharmaceuticals, Inc. |
(Exact Name of Registrant as Specified in Charter) |
Delaware |
000-50743 |
77-0602661 |
(State or Other Juris- diction of Incorporation)
|
(Commission File Number) |
(IRS Employer Identification No.) |
300 Third Street, Cambridge, MA |
02142 |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
telephone number, including area code: (617) 551-8200
Not applicable |
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition
On May 2, 2011, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2011. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific reference in
such a filing.
Item 5.02. Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(b) On April 30, 2011, Vicki L. Sato, Ph.D. retired from the Board
of Directors (the “Board”) of the Company. Dr. Sato served as a
valuable member of the Company’s Board from 2005 until her retirement.
Item
9.01. Financial Statements and Exhibits
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
99.1 Press Release dated May 2, 2011.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: May 2, 2011 |
ALNYLAM PHARMACEUTICALS, INC. |
||
|
|||
|
By: |
/s/ Michael P. Mason |
|
Michael P. Mason |
|||
Vice President, Finance and Treasurer |
EXHIBIT INDEX
Exhibit No. | Description | ||
99.1 |
Press Release dated May 2, 2011 |